Urinary Tract Infection Therapeutics Market Size, Share, and Industry Analysis, By Drug Class (Antibiotics, Antifungal, and Others), By Route of Administration (Oral and Parenteral), By Age Group (Pediatric and Adult), By Indication (Uncomplicated Urinary Tract Infections (uUTI), Complicated Urinary Tract Infections (cUTI), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2026-2034

The global urinary tract infection therapeutics market size was valued at USD 10.03 billion in 2025. The market is projected to grow from USD 10.45 billion in 2026 to USD 14.49 billion by 2034, exhibiting a CAGR of 4.17% during the forecast period.

The global urinary tract infection therapeutics market is witnessing significant growth due to the rise in the incidence of urinary tract infections, especially among women. Additionally, an increase in the aging population and associated conditions, such as diabetes and kidney stones, increases the risk of UTIs, which further fuels the market growth. Moreover, new product launches and regulatory approvals also support market growth. 

• For instance, in October 2025, Iterum Therapeutics plc., received approval from the U.S. FDA for ORLYNVAH to treat uncomplicated urinary tract infections.

Urinary Tract Infection Therapeutics Market Driver

Rise in Incidence of Urinary Tract Infection Drives Market Growth

The rise in the incidence of urinary tract infections drives the market growth during the forecast period. An increase in the aging population, the rising awareness about UTIs, and advancements in diagnostic technologies are some of the factors that are responsible for the rise in the incidence of UTIs. This increases the demand for effective treatment options, which increases the product adoption rate. 

• For instance, according to the data published by the Urology Care Foundation in November 2022, approximately 12 % of men and 60% of women have at least one urinary tract infection in their lifetime.

Global Prevalence of Urinary Tract Infection (in percentage), By Gender, 2022

According to the data published by the Urology Care Foundation in 2022, women are more prone to urinary tract infections as compared to men. The graph shows that the prevalence of urinary tract infection in women was 60%.

Urinary Tract Infection Therapeutics Market Restraint

Adverse Effects Associated with the Use of UTI Medication May Hinder Market Growth

Adverse effects associated with long-term UTI medications, such as antibiotic resistance, may hamper the growth of the urinary tract infection therapeutics market. The side effects of these medications can range from mild to severe, which may lower the adoption rate of products and slower the market growth during the forecast period.

• For instance, according to the data published by the National Center for Biotechnology Information in July 2023, long-term use of Nitrofurantoin can show side effects, such as hepatotoxicity, neuropathy, and pulmonary damage. This may have resulted in lowering the market growth.

Urinary Tract Infection Therapeutics Market Opportunity

Novel Antibiotic Development May Offer Growth Opportunities in Future

The development of novel antibiotics may offer lucrative growth opportunities in the future. This is due to increased antibiotic resistance and rising regulatory approvals. Additionally, a rise in antimicrobial resistance is leading to an increase in the demand for effective medications to treat urinary tract infections. Effective and advanced medications are expected to increase the product adoption rate in the future. 

• For instance, in January 2024, UTILITY Therapeutics Ltd. announced the acceptance of a New Drug Application (NDA) for PIVYA and financing led by the AMR (antimicrobial resistance) action fund.

Key Insights

The report covers the following key insights:

• Prevalence of Urinary Tract Infections, By Key Countries/Regions, 2024
• Pipeline Analysis, By Key Players
• New Product Launches, By Key Players
• Key Industry Developments - Mergers, Acquisitions, Partnerships, etc.

Segmentation

Analysis by Drug Class

By drug class, the market is divided into antibiotics, antifungal, and others.

The antibiotics segment accounted for a significant revenue in the market. This growth is due to its effectiveness in the treatment of complicated and uncomplicated urinary tract infections. Additionally, the rise in the adoption rate of UTI products based on antibiotics and their widespread use also supports the segment growth during the forecast period.

• For instance, in March 2025, GSK plc received approval from the U.S. FDA for Blujepa (gepotidacin), an antibiotic used for the treatment of uncomplicated urinary tract infections (uUTIs) in female adults and pediatric patients.

Analysis by Route of Administration 

Based on the route of administration, the market is segmented into oral and parenteral. The oral segment held a significant share of the urinary tract infection therapeutics market in 2024. This is due to its ease of administration and high patient preference. The majority of uncomplicated UTIs are treated with oral antibiotics, resulting in high patient compliance and regulatory approvals, which increases the product adoption rate and drives the market growth.

• For instance, in October 2024, Iterum Therapeutics received approval from the U.S. FDA for Orlynvah, an oral antibiotic used for the treatment of uncomplicated UTIs in adult women.

Analysis by Age Group

Based on age, the market is classified into adult and pediatric segments. The adult segment held a significant portion of the urinary tract infection therapeutics market. The growth of the segment is attributed to the rise in the prevalence of urinary tract infections in adults, especially in women. Additionally, the rise in the aging population, which is more susceptible to these infections, further supports the growth of the segment. 

• For instance, according to the data published by the Annals of Epidemiology in April 2025, the lifetime prevalence of urinary tract infection in women was 53%, and in men, it was 14%.

Analysis by Indication

On the basis of indication, the market is classified into uncomplicated urinary tract infections (uUTI), complicated urinary tract infections (cUTI), and others. The complicated urinary tract infections held a prominent share of the market in 2024. This is primarily due to the rise in the prevalence of drug-resistant bacteria and the overuse of antibiotics, which increases the cases of cUTI. Additionally, product launches and government support also support the segmental growth. 

• In February 2024, Cipla Inc. received approval for Plazomicin, used in the treatment of complicated urinary tract infections (cUTI) from the Central Drugs Standard Control Organization (CDSCO).

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.

Hospital pharmacies held accountable share of the market in 2024. This is due to their access to a wide range of medications, including oral and intravenous UTI medications. Additionally, hospital pharmacies are often involved in managing catheter-associated UTIs (CAUTIs), which are a common complication in hospital settings.

• For instance, in September 2024, Pharmaprix, a pharmacy chain, announced expanding the care clinic network. These innovative clinics, averaging 450 square feet and offer a range of primary care services, including treatment for urinary tract infections.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a substantial share of the global urinary tract infection therapeutics market in 2024. The rise in incidence of urinary tract infections propels the market growth during the forecast period. Furthermore, government initiatives, such as awareness programs, support the market growth.

• For instance, according to data published by Medscape, in January 2025, in the U.S., approximately 20% of women suffer at least one UTI in their lifetime.

Europe has a significant share of the global urinary tract infection market. The growth of the region can be attributed to a strong focus on the development of new therapies to treat urinary tract infections. Additionally, the rising geriatric population, who have high chances of getting infected, is expected to increase the patient population and further drive the market growth.

Asia Pacific is the fastest-growing region during the forecasting years. Pharmaceutical companies are shifting their locations from Western countries to this region due to the large patient pool. The growing geriatric population, increasing urbanization, and large patient pool drive the market growth in this region.

Key Players Covered

The global urinary tract infection market is fragmented with a few key players. The report includes the profiles of the following key players:

• Shionogi Inc. (Japan)
• Iterum Therapeutics plc. (U.S.)
• GSK plc. (U.K.)
• Sun Pharmaceutical Industries, Inc. (India)
• Casper Pharma LLC (India)
• Cipla Inc. (India)
• Bayer AG (Germany)
• AstraZeneca (U.K.)

Key Industry Developments

• In April 2024, the U.S. FDA approved Pivya (pivmecillinam) tablets for the treatment of uncomplicated urinary tract infections (UTIs) in female adults.
• In February 2024, Allecra Therapeutics GmbH received approval from the U.S. FDA for EXBLIFEP to treat complicated Urinary Tract Infections (cUTIs).